**Introduction**

Vasomotor symptoms (VMS), including hot flushes, night sweats, and sweating are a common complaint of postmenopausal women1,2 and have been associated with significant quality of life (QoL) decrements.3-5 Synthetic and natural hormone therapies have been shown to be effective in reducing VMS.6-8 Due to serious safety concerns with estrogen alone, bioidentical estrogen (E2)/progesterone (P4) products have been developed as a safe and effective treatment for VMS.9-11

**Objective**

The REPLENISH trial (NCT01942668) was a phase 3, randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of Bijuva, a 1 mg E2/100 mg P4 product that is FDA-approved, in reducing VMS in postmenopausal women1,2

**Methods**

Women aged 40 to 65 years of age and postmenopausal; a current or previous hysterectomy; and a serum estradiol level of <40 pg/mL were included. Participants were randomized to 1 mg E2/50 mg P4, 0.5 mg E2/100 mg P4, 0.5 mg E2/50 mg P4, or placebo in a VMS substudy; other women (with less frequent VMS) were randomized to 1 mg E2/100 mg P4.

**Results**

Mean change from placebo in the MENQOL (A) hot flushes, (B) night sweats, and (C) sweating in MITT-VMS population

**Conclusions**

The 1 mg E2/100 mg P4 dose, the first combined bioidentical E2/P4 product that is FDA-approved, Bijuva, significantly reduced VMS duration and severity in postmenopausal women. These results are consistent with the primary results of the REPLENISH trial demonstrating efficacy for the treatment of VMS in the MITT and MITT-VMS populations.